Infections, Monkeypox, Therapeutics, Treatment Efficacy, Orthopoxvirus

1. Ferrer R. Pandemia por COVID-19: el mayor reto de la historia del intensivismo. Med Intensiva. 2020 Aug;44(6):323-4. https://doi.org/10.1016/j.medin.2020.04.002
2. Khardori N. Vaccines and vaccine resistance: past, present and future. Indian J Med Microbiol. 2022 Apr;40(2):187-92. https://doi.org/10.1016/j.ijmmb.2021.12.008
3. Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, et al. Human Monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am. 2019 Dec;33(4):1027-43. https://doi.org/10.1016/j.idc.2019.03.001
4. Thèves C, Biagini P, Crubézy E. The rediscovery of smallpox. Clin Microbiol Infect. 2014 Mar;20(3):210-8. https://doi.org/10.1111/1469-0691.12536
5. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs. 2022 Jun 28;82(9):957-63. https://doi.org/10.1007/s40265-022-01742-y
6. McCollum AM, Damon IK. Human Monkeypox. Clin Infect Dis. 2014 Jan 15;58(2):260-7. https://doi.org/10.1093/cid/cit703
7. Sudarmaji N, Kifli N, Hermansyah A, Yeoh SF, Goh BH, Ming LC. Prevention and treatment of monkeypox: a systematic review of preclinical studies. Viruses. 2022 Nov 11;14(11):2496. https://doi.org/10.3390/v14112496
8. Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018 Jul 5;379(1):44-53. https://doi.org/10.1056/NEJMoa1705688
9. Russo AT, Grosenbach DW, Brasel TL, Baker RO, Cawthon AG, Reynolds E, et al. Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. J Infect Dis. 2018 Sep 22;218(9):1490-9. https://doi.org/10.1093/infdis/jiy326
10. Smith SK, Self J, Weiss S, Carroll D, Braden Z, Regnery RL, et al. Effective antiviral treatment of systemic orthopoxvirus disease: st-246 treatment of prairie dogs infected with monkeypox virus. J Virol. 2011 Sep;85(17):9176-87. https://doi.org/10.1128/JVI.02173-10
11. Filippov E, Duhan S, Lehman L, Keisham B, Sethi V. Treatment failure in patient with severe Mpox and untreated HIV, Maryland, USA. Emerg Infect Dis. 2023 Jun;29(6). https://doi.org/10.3201/eid2906.230059
12. Shamim MA, Padhi BK, Satapathy P, Veeramachaneni SD, Chatterjee C, Tripathy S, et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int J Infect Dis. 2023 Feb;127:150-61. https://doi.org/10.1016/j.ijid.2022.11.040
13. Lim EY, Whitehorn J, Rivett L. Monkeypox: a review of the 2022 outbreak. Br Med Bull. 2023 Apr 5;145(1):17-29. https://doi.org/10.1093/bmb/ldad002
14. Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Nat Acad Sci. 2010 Jan 12;107(2):838-43. https://doi.org/10.1073/pnas.0912134107
15. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022 Aug;22(8):1153-62. https://doi.org/10.1016/S1473-3099(22)00228-6
16. Beatty NL, Small C, Degener T, Henao Martinez AF. Monkeypox infection and resolution after treatment with tecovirimat in two patients with HIV disease. Ther Adv Infect Dis. 2022 Jan 21;9:204993612211383. https://doi.org/10.1177/20499361221138349
17. Warner BM, Klassen L, Sloan A, Deschambault Y, Soule G, Banadyga L, et al. In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate. Sci Transl Med. 2022 Nov 30;14(673). https://doi.org/10.1126/scitranslmed.ade7646
18. O’Laughlin K, Tobolowsky FA, Elmor R, Overton R, O’Connor SM, Damon IK, et al. Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol — United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-5. https://doi.org/10.15585/mmwr.mm7137e1
19. McLean J, Stoeckle K, Huang S, Berardi J, Gray B, Glesby MJ, et al. Tecovirimat treatment of people with HIV During the 2022 Mpox outbreak. Ann Intern Med. 2023 May;176(5):642-8. https://doi.org/10.7326/M22-3132
20. Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE, Damon IK. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother. 2009 Mar;53(3):1007-12. https://doi.org/10.1128/AAC.01044-08
21. Roper RL, Garzino-Demo A, Del Rio C, Bréchot C, Gallo R, Hall W, et al. Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies. Vaccine. 2023 May;41(20):3171-7. https://doi.org/10.1016/j.vacuna.2023.04.010
22. DeLaurentis CE, Kiser J, Zucker J. New perspectives on antimicrobial agents: tecovirimat for treatment of human monkeypox virus. Antimicrob Agents Chemother. 2022 Dec 20;66(12). https://doi.org/10.1128/aac.01226-22
23. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev. 2001 Apr;14(2):382-97. https://doi.org/10.1128/CMR.14.2.382-397.2001
24. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002 Jul;55(1):1-13. https://doi.org/10.1016/s0166-3542(02)00008-6
25. Moschese D, Giacomelli A, Beltrami M, Pozza G, Mileto D, Reato S, et al. Hospitalisation for monkeypox in Milan, Italy. Travel Med Infect Dis. 2022 Sep;49:102417. https://doi.org/10.1016/j.tmaid.2022.102417
26. Stafford A, Rimmer S, Gilchrist M, Sun K, Davies EP, Waddington CS, et al. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection. Lancet Infect Dis. 2023 Jun;23(6):e218-26. https://doi.org/10.1016/S1473-3099(23)00044-0
27. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 2006 Feb 9;439(7077):745-8. https://doi.org/10.1038/naturaleza04295
28. Bloch EM, Sullivan DJ, Shoham S, Tobian AAR, Casadevall A, Gebo KA. The potential role of passive antibody-based therapies as treatments for monkeypox. mBio. 2022 Dec 20;13(6). https://doi.org/10.1128/mbio.02862-22
29. Kuroda N, Shimizu T, Hirano D, Ishikane M, Kataoka Y. Lack of clinical evidence of antiviral therapy for human monkeypox: a scoping review. J Infect Chemother. 2023 Feb;29(2):228-31. https://doi.org/10.1016/j.jiac.2022.10.009
30. Malik S, Ahmad T, Ahsan O, Muhammad K, Waheed Y. Recent developments in Mpox prevention and treatment options. Vaccines (Basel). 2023 Feb 21;11(3):500. https://doi.org/10.3390/vacunas11030500
31. Quenelle D, Collins D, Kern E. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res. 2004 Jul;63(1):33-40. https://doi.org/10.1016/j.antiviral.2004.02.003
32. Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother. 2003 Oct;47(10):3275-80. https://doi.org/10.1128/AAC.47.10.3275-3280.2003
33. Mark Miller, Scott Barrett, DA Henderson. Chapter 62: Control and eradication. En: Jamison DT, Breman JG, Measham AR, Dean T Jamison, Joel G Breman, Anthony R Measham, et al., editores. Disease control priorities in developing countries. 2.ª ed. Washington (DC): World Bank Publications; 2006.
34. Martín-Delgado MC, Martín-Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo F, et al. Monkeypox in humans: a new outbreak. Rev Esp Quimioter. 2022 Jul 6. https://doi.org/10.37201/solicitud/059.2022
35. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141. https://doi.org/10.1371/journal.pntd.0010141
36. Mileto D, Riva A, Cutrera M, Moschese D, Mancon A, Meroni L, et al. New challenges in human monkeypox outside Africa: a review and case report from Italy. Travel Med Infect Dis. 2022 Sep;49:102386. https://doi.org/10.1016/j.tmaid.2022.102386
37. De Sousa D, Patrocínio J, Frade J, Correia C, Borges-Costa J, Filipe P. Human monkeypox coinfection with acute HIV: an exuberant presentation. Int J STD AIDS. 2022 Sep 13;33(10):936-8. https://doi.org/10.1177/09564624221114998
38. Gonzalo-Salado M, García-Sánchez S, Silva-Cuevas M, García-Luque A. Evaluación positiva de medicamentos: septiembre, octubre, noviembre y diciembre de 2021. Sanidad Militar. 2022 Sep 19;78(1):33-41. https://doi.org/10.4321/s1887-85712022000100007.
39. Organización Panamericana de la Salud. Opciones terapéuticas para la viruela símica: síntesis de evidencia. Revisión rápida. Washington; 2022.
40. Siegrist EA, Sassine J. Antivirals with activity against mpox: a clinically oriented review. Clin Infect Dis. 2023 Jan 6;76(1):155-64. https://doi.org/10.1093/cid/ciac622
41. Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021 Mar 4;19(3):331-44. https://doi.org/10.1080/14787210.2020.1819791
42. Shamim MA, Padhi BK, Satapathy P, Veeramachaneni SD, Chatterjee C, Tripathy S, et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int J Infect Dis. 2023 Feb;127:150-61. https://doi.org/10.1016/j.ijid.2022.11.040
43. Almehmadi M, Allahyani M, Alsaiari AA, Alshammari MK, Alharbi AS, Hussain KH, et al. A glance at the development and patent literature of tecovirimat: the first-in-class therapy for emerging monkeypox outbreak. Viruses. 2022 Aug 25;14(9):1870. https://doi.org/10.3390/v14091870
44. Kumar AM, Chen ST, Merola JF, Mostaghimi A, Zhou XA, Fett N, et al. Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: review and interim guidance from the Medical Dermatology Society. J Am Acad Dermatol. 2023 Mar;88(3):623-31. https://doi.org/10.1016/j.jaad.2022.10.050
45. Huston J, Curtis S, Egelund EF. Brincidofovir: a novel agent for the treatment of smallpox. Ann Pharmacother. 2023 Jan 23;106002802311517. https://doi.org/10.1177/10600280231151751
46. Siegrist EA, Sassine J. Antivirals with activity against mpox: a clinically oriented review. Clin Infect Dis. 2023 Jan 6;76(1):155-64. https://doi.org/10.1093/cid/ciac622
47. Mateos Moreno D, Clavo Escribano P. Infección por virus de la viruela del mono: caso clínico. Actas Dermosifilogramas. 2023 Jan;114(1):83-5. https://doi.org/10.1016/j.ad.2022.06.014
48. Kukreja S, Ochani S, Kalwar A, Lohana S, Ullah K. Re-administration of SmallPox vaccine against MonkeyPox among general population; after more than 30 Years of vaccine cessation by WHO. Ann Med Surg. 2022 Sep;81. https://doi.org/10.1016/j.amsu.2022.104519
49. Mungmunpuntipantip R, Wiwanitkit V. Smallpox vaccination discontinuation and monkeypox incidence in an African endemic region: a reanalysis on the relationship between the withdrawal of smallpox vaccine and subsequent morbidity. Am J Clin Exp Immunol. 2022;11(5):78-83.
50. Kumar P, Chaudhary B, Yadav N, Devi S, Pareek A, Alla S, et al. Recent advances in research and management of human monkeypox virus: an emerging global health threat. Viruses. 2023 Apr 10;15(4):937. https://doi.org/10.3390/v15040937

Vol. 64 Núm. 4 (2023)